Romidepsin + Azacitidine + nab-Paclitaxel + Gemcitabine + Durvalumab + Lenalidomide capsule
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreas Cancer
Conditions
Pancreas Cancer, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Trial Timeline
May 25, 2020 → Jul 2, 2024
NCT ID
NCT04257448About Romidepsin + Azacitidine + nab-Paclitaxel + Gemcitabine + Durvalumab + Lenalidomide capsule
Romidepsin + Azacitidine + nab-Paclitaxel + Gemcitabine + Durvalumab + Lenalidomide capsule is a phase 1/2 stage product being developed by AstraZeneca for Pancreas Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04257448. Target conditions include Pancreas Cancer, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma.
What happened to similar drugs?
1 of 5 similar drugs in Pancreas Cancer were approved
Approved (1) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04257448 | Phase 1/2 | Completed |
Competing Products
20 competing products in Pancreas Cancer